ISRG AI Stock Analysis

AlphaCrew

Intuitive Surgical, Inc. (ISRG)

Fundamentals

Essentia

Fundamental Analysis

BULLISH

Intuitive Surgical (ISRG) maintains strong fundamentals with consistent revenue and earnings growth, driven by its leadership in robotic surgical systems. Profitability remains robust with expanding gross and operating margins, supported by efficient cost management and growing adoption of its technology globally. While current valuation reflects a premium, ISRG's strong innovation pipeline and market position underpin its growth potential despite some valuation and macro risks.

Overview

ISRG designs, manufactures, and sells robotic surgical systems, instruments, and accessories primarily for minimally invasive surgery. Its flagship da Vinci Surgical System is used worldwide across multiple specialties, enabling surgeons to perform complex procedures with enhanced precision and control.

Market Position

ISRG holds a dominant market share in robotic-assisted surgery with a well-established installed base. It has strong relationships with hospitals and surgeons, benefiting from high switching costs and a growing addressable market in both developed and emerging healthcare systems.

Competitive Advantages

The company boasts proprietary technology, high clinical efficacy, and a strong brand name. Continuous innovation via R&D investments, a comprehensive ecosystem of instruments and training, and intellectual property protections create significant competitive moats that are difficult for new entrants to overcome.

✓ Market leadership in robotic surgical systems with strong brand and installed base✓ Consistent revenue and earnings growth with expanding margins✓ Robust innovation pipeline and recurring consumables revenue model⚠ High valuation metrics relative to sector and historical averages⚠ Potential competitive threats from emerging players and new technologies⚠ Exposure to healthcare capital expenditure cycles and regulatory environments

Financial Highlights

Revenue
Net Income
Net Margin (%)

Revenue

$2.89B

18.54% YoY

Q2 2026

Net Income

$818.10M

24.26% YoY

Q2 2026

Net Margin

28.29%

Q2 2026

Growth Metrics

Profitability Metrics

Technical Analysis

Candela

Technical Analysis

BEARISH

ISRG is currently in a strong downtrend, trading below critical moving averages with a bearish death cross signaling continued weakness. Momentum is neutral but leans bearish, and the stock is in Stage 4 decline phase, indicating caution for traders. Price is near its 52-week low and well below the 50, 150, and 200-day SMAs, reinforcing the negative technical outlook.

Key Insights

Strong downtrend confirmed by price below 50, 150, and 200 SMAs with death cross formation. RSI near 40 shows neutral momentum without oversold conditions. ADX at 24 indicates a moderate but developing bearish trend. Stage analysis places ISRG in a declining phase, recommending avoidance or short positions.

Trend Analysis

Primary trend is bearish with strong downward pressure as price trades well below major moving averages. Secondary trend is similarly bearish with no signs of reversal, indicating alignment in downward momentum.

Momentum

Momentum is currently neutral to bearish. RSI is not yet oversold, suggesting potential further downside or sideways consolidation. ADX shows moderate trend strength but no definitive momentum acceleration.

Price Targets

Downside target near $328.57 (52-week low) with potential to test lower levels if breakdown occurs. Resistance overhead in the $395-$400 range tied to SMA50, then $480 area near SMA200 if any rally occurs.

Entry Zone

Consider short entries at rallies approaching $395-$400 resistance levels or wait for confirmed breakdown below $328.57 for increased downside momentum. Long entries are not recommended until a clear stage 1 base is confirmed.

RSI

Hold

Neutral50

No extreme reading

03070100

Trend

Sell

Strong Downtrend

Price in downtrend

-22.0% from 200 SMA

ADX

Hold

Moderate Trend23

Trend developing

Moderate

MA Cross

Sell

Below 50/200

50 below 200 - bearish

50

↓

200

Key Technical Values

Price

$375.41

50 SMA

$397.92

150 SMA

$459.68

200 SMA

$481.57

52W High

$603.88

52W Low

$328.57

Price with Moving Averages

50-day, 150-day and 200-day simple moving averages

Price

50 SMA

150 SMA

200 SMA

Relative Strength Index

Momentum oscillator measuring speed and magnitude of price changes

RSI (14)

≤30 Oversold

≥70 Overbought

50Neutral

Earnings

Essentia

Fundamental Analysis

BULLISH

Intuitive Surgical (ISRG) maintains strong fundamentals with consistent revenue and earnings growth, driven by its leadership in robotic surgical systems. Profitability remains robust with expanding gross and operating margins, supported by efficient cost management and growing adoption of its technology globally. While current valuation reflects a premium, ISRG's strong innovation pipeline and market position underpin its growth potential despite some valuation and macro risks.

Latest Earnings

Q2 2026 Earnings (Jun 30, 2026)

Earnings Per Share (EPS)

Beat

Actual

$2.80

Estimated

$2.48

Surprise

+$0.32

Surprise %

+12.90%

Revenue

Beat

Actual

$2.89B

Estimated

$2.83B

Surprise

+$66.97M

Surprise %

+2.37%

Historical Earnings

	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024
Earnings Per Share
EPS (Actual)	$2.80	$2.80	$2.53	$2.40	$2.19	$1.81	$2.21	$1.84
EPS (Estimated)	$2.48	$2.51	$2.27	$1.99	$1.93	$1.74	$1.76	$1.63
EPS Surprise	+$0.32	+$0.29	+$0.26	+$0.41	+$0.26	+$0.07	+$0.45	+$0.21
% Diff	+12.9%	+11.6%	+11.5%	+20.6%	+13.5%	+4.0%	+25.6%	+12.9%
Revenue
Revenue (Actual)	$2.89B	$2.77B	$2.87B	$2.51B	$2.44B	$2.25B	$2.41B	$2.04B
Revenue (Estimated)	$2.83B	$2.62B	$2.76B	$2.41B	$2.35B	$2.19B	$2.25B	$2.01B
Revenue Surprise	+$66.97M	+$152.05M	+$103.57M	+$98.71M	+$88.75M	+$67.59M	+$164.64M	+$32.62M
% Diff	+2.4%	+5.8%	+3.7%	+4.1%	+3.8%	+3.1%	+7.3%	+1.6%

Valuation

Valorem

Valuation Analysis

FAIRLY VALUED

Intuitive Surgical's current valuation reflects a premium growth stock with robust financial health and strong operational metrics. While the stock price has corrected significantly in 2026, analyst consensus remains positive, citing strong revenue and earnings growth alongside expanding procedure adoption. The valuation multiples suggest the market is pricing in growth uncertainties but still assigns a premium given the industry-leading position.

Overview

Collectively, Intuitive Surgical's valuation metrics show a premium yet moderated valuation compared to its historical peaks and some peers, with high P/E and EV/EBITDA ratios reflecting strong growth expectations and high margins. The company exhibits healthy profitability, substantial cash flow, and negligible debt, supporting its valuation. The price-to-sales and price-to-book ratios remain elevated, consistent with a high-growth medical technology leader.

Sector Comparison

Compared to the healthcare sector, especially within medical instruments and supplies, ISRG trades at multiples higher than average peers. However, it demonstrates superior revenue growth and margins, justifying a premium relative to the sector's generally lower multiple averages. The company's operational efficiency and innovation pipeline enhance its differentiated valuation stance versus more traditional medical device makers.

Standout Metrics

The standout metrics are the elevated EV/EBITDA ratio and the very high price-to-sales multiple, which are among the highest in the sector, underscoring growth expectations priced into the stock. The strong gross and operating margins further support these valuations. Notably, the return on equity and assets are solid, though slightly diminished in the latest quarter, which may reflect growth investments or margin pressures.

Valuation Metrics

Sentiment & Analyst Ratings

Pulse

Sentiment Analysis

MIXED

Intuitive Surgical's (ISRG) market sentiment is moderately positive, supported by strong Q2 earnings beats and continued global system placements despite a significant YTD stock decline. Analysts mostly maintain buy ratings with attractive price targets reflecting confidence in its recurring revenue and growth platforms, though concerns about slowing U.S. procedure growth and competition temper enthusiasm. Retail and social sentiment appear mixed, mirroring broader market caution amid structural risks and recent volatility.

Key Themes

Strong financial performance with record revenue and margins, global system placement growth, tempered by concerns on moderating U.S. procedure growth, competition from emerging surgical robots, and healthcare policy changes affecting procedure volume. Management's share buybacks indicate confidence.

Recent Developments

Q2 2026 earnings outperformed expectations, with revenue up 18.4% YoY and robust gross margins. Installed base of da Vinci systems increased 18% in Q2. Notable analyst upgrades and revisions of price targets upwards and downwards reflect divergent views. Executive insider selling under 10b5-1 plan has minor impact.

Media Coverage

Increasing media coverage due to earnings release and analyst activity, with tone balanced: positive on growth and profitability but cautious on headwinds and stock price performance.

Analyst Sentiment

Analysts broadly favor ISRG with a consensus moderate buy, though target prices vary significantly ($324 to $750). Some recently upgraded ratings and reaffirmations highlight strong company fundamentals; downgrades reflect caution about near-term growth challenges and valuation risks.

Analyst Recommendations

As of Aug 1, 2026

Strong SellSellHoldBuyStrong Buy

Buy

3.9 / 5.0

Based on 33 analyst ratings

Strong Sell

0

Sell

1

Hold

9

Buy

16

Strong Buy

7

Risk Assessment

Sentinel

Risk Assessment

MODERATE

Intuitive Surgical demonstrates a strong financial position with exceptionally high liquidity and minimal debt, supporting resilience against short-term shocks. Despite facing competitive pressures, supply chain challenges, and structural shifts in procedure volumes, the company maintains robust growth in procedures and margins, reflecting operational strength. However, high valuation multiples and sector-specific risks warrant a cautious but optimistic investor outlook.

Key Risk Factors

Key risks include China market reimbursement uncertainty, tariff-driven margin pressures, competition from emerging robotic surgery providers, procedural volume impact from GLP-1 drug adoption, and regulatory changes affecting procedure demand.

Risk vs Sector

Compared to peers in the medical instruments and surgical robotics sector, Intuitive Surgical carries moderate risk given its market leadership offset by high exposure to geopolitical and pricing risks in key regions like China and supply chain vulnerabilities.

Risk Summary

While Intuitive Surgical's financial health is strong, its business risks are elevated by external factors such as regulatory uncertainty, competitive encroachment, and procedure volume disruptions. These risks are balanced by strong operational results, innovation leadership, and solid market growth forecasts, resulting in a moderate overall risk profile.

Liquidity & Solvency

Frequently Asked Questions about ISRG

AI Answers: Common Questions About ISRG

Get AI-powered answers to the questions investors ask most about Intuitive Surgical, Inc.

ISRG is a good long-term buy given its strong fundamentals, market leadership, and growth prospects. The stock trades at a P/E of 36.73 with expanding margins and consistent revenue growth above 20% year-over-year, supporting a premium valuation.

Short-term traders may consider selling or avoiding new positions due to bearish technical signals including a death cross and price near 52-week lows around $328.57. Long-term investors should hold unless fundamental deterioration occurs.

Key risks include competition from new robotic systems, regulatory and reimbursement uncertainties especially in China, and potential procedure volume declines from GLP-1 drug impacts and healthcare policy changes.

Analyst price targets vary widely from $324 to $750, with consensus near $485-$500 reflecting growth expectations balanced by valuation and risk concerns.

ISRG is fairly valued with a P/E of 36.73, elevated EV/EBITDA and price-to-sales multiples justified by strong double-digit revenue and earnings growth, high margins near 67% gross and 33% operating, and recurring revenue streams.

The company shows consistent revenue growth surpassing $10 billion annually, improving operating margins over 33%, and EPS growth exceeding estimates by over 12%. It maintains a strong balance sheet with negligible debt and high liquidity ratios.

The technical outlook is bearish with price below 50, 150, and 200-day SMAs, a death cross, and momentum indicators neutral to bearish. Support is near $328.57 with resistance around $395-$400, suggesting limited near-term upside.

Potential catalysts include new system launches like da Vinci 5, expansion into new markets and clinical indications, and continued global adoption of robotic surgery driving procedure volume growth.

Want a Personalized Answer?

Get AI-powered insights tailored to your risk tolerance and investment goals.

More AI Stock Analyses

AAPL NVDA TSLA MSFT AMZN GOOGL View All

ISRG AI Stock Analysis – Buy, Hold, or Avoid?

Intuitive Surgical, Inc. (ISRG)

Fundamentals

Financial Highlights

Revenue

Net Income

Net Margin

Growth Metrics

Profitability Metrics

Technical Analysis

Key Technical Values

Price with Moving Averages

Relative Strength Index

RSI (14)

Earnings

Latest Earnings

Q2 2026 Earnings (Jun 30, 2026)

Earnings Per Share (EPS)

Revenue

Historical Earnings

Valuation

Valuation Metrics

Sentiment & Analyst Ratings

Analyst Recommendations

Risk Assessment

Liquidity & Solvency

Frequently Asked Questions about ISRG

AI Answers: Common Questions About ISRG

Is ISRG stock a good buy right now?AI

Should I sell ISRG stock now?AI

What are the biggest risks for ISRG stock?AI

What is the ISRG price target or forecast for the next 12 months?AI

Is ISRG overvalued or undervalued right now?AI

Is ISRG fundamentally strong?AI

What does technical analysis say about ISRG support and resistance?AI

What are the key catalysts to watch for ISRG?AI

Want a Personalized Answer?

More AI Stock Analyses